A new oral medication, Lipfendra, has been approved in the USA for lowering cholesterol levels, which is the first PCSK9 inhibitor and has shown a significant reduction in "bad cholesterol" by 56-59% in clinical trials. (translated)
The U.S. Food and Drug Administration has approved a new oral cholesterol medication called Lipfendra, which is the first PCSK9 inhibitor and allows for more effective control of high cholesterol. (translated)
In the USA, the first tablet of the new drug class of PCSK9 inhibitors has been approved, which is intended to help high-risk patients lower their cholesterol levels more effectively as a cost-effective supplement to statin therapy, without the need for injections. (translated)
Американската Агенция по храните и лекарствата одобри Lipfendra, първия орален инхибитор на PCSK9 за понижаване на „лошия“ LDL холестерол, който показва значително намаляване на нивата на холестерола при пациенти с хиперхолестеролемия и сърдечносъдови заболявания. #Lipfendra #холестерол #PCSK9
V USA byla schválena první tableta nového typu cholesterinového léku, PCSK9-inhibitoru Enlicitide, což by mohlo usnadnit léčbu pacientům, kteří nedosahují svých cílových hodnot cholesterolu pomocí statinů, a přinést výhody v nákladech a dostupnosti. #Cholesterinsenker #PCSK9Hemmer #Gesundheit
Amerikanska Merck har fått godkännande i USA för läkemedlet Lipfendra, som är det första orala alternativet med en daglig dosering inom PCSK9-hämmar-klassen. #Merck #PCSK9 #Läkemedel
